Ann: MX1 - AGM CEO Presentation, page-12

Emvision should not count its chickens. It is not totally proven yet, let alone approved. I think it likely that the FDA will require stringent proof that it is effective, since it is a technology not used before to distinguish stroke types. Since the research into Micro X 's technology is being funded by the Stroke Alliance (not sure of the name)(or so they claim anyway), they should probably proceed with it. MicroX may still be the winner.
My flippant comment after the AGM , that the SP had not been slammed, referred to my idea after the shambolic presentation that investors might punish the company for being a tech company that could not even get the technology right for the presentation.
Of course, it has slid lower since - no wonder , when catalysts are so far away